Mazen Noureddin
Overview
Explore the profile of Mazen Noureddin including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
265
Citations
5857
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Danpanichkul P, Pang Y, Inkongngam T, Namsathimaphorn K, Rakwong K, Kaeosri C, et al.
Cancer Commun (Lond)
. 2025 Feb;
PMID: 40017390
No abstract available.
2.
Alkhouri N, Charlton M, Gray M, Noureddin M
Expert Opin Investig Drugs
. 2025 Feb;
PMID: 40016997
Introduction: Glucagon-like peptide-1 receptor agonists (GLP-1RAs), and dual GLP-1/glucose-dependent insulinotropic peptide (GIP) or glucagon receptor agonists have emerged as promising agents to treat metabolic dysfunction-associated steatotic liver disease (MASLD)/metabolic dysfunction-associated...
3.
Danpanichkul P, Suparan K, Auttapracha T, Tothanarungroj P, Kongarin S, Rakwong K, et al.
Mayo Clin Proc
. 2025 Feb;
PMID: 39945699
Objective: To explore the increasing incidence of gastrointestinal (GI) cancers and related risk factors in younger patients. Patient And Methods: We used data from the Global Burden of Disease Study...
4.
Kalligeros M, Danpanichkul P, Noureddin M
Gastroenterol Hepatol (N Y)
. 2025 Jan;
20(11):672-677.
PMID: 39886331
Metabolic dysfunction-associated steatotic liver disease (MASLD), previously termed nonalcoholic fatty liver disease, is a major global health issue and a leading cause of chronic liver disease. The prevalence of MASLD...
5.
Danpanichkul P, Diaz L, Suparan K, Tothanarungroj P, Sirimangklanurak S, Auttapracha T, et al.
Clin Mol Hepatol
. 2025 Jan;
PMID: 39788109
Background/aims: Alcohol represents a leading burden of disease worldwide, including alcohol use disorder (AUD) and alcohol-related liver disease (ALD). We aim to assess the global burden of AUD, ALD, and...
6.
Danpanichkul P, Suparan K, Pang Y, Auttapracha T, Tham E, Srisurapanont K, et al.
Am J Med
. 2025 Jan;
PMID: 39778787
Objective: Gastrointestinal (GI) cancers account for one-third of global cancer mortality, with nearly half being preventable. This study updates the global burden of GI cancers attributed to major risk factors....
7.
Danpanichkul P, Pang Y, Suparan K, Auttapracha T, Sirimangklanurak S, Attia A, et al.
Hepatol Commun
. 2025 Jan;
9(1.
PMID: 39773868
Background: The incidence of cancer and the prevalence of metabolic disease and metabolic dysfunction-associated steatotic liver disease is increasing in young adults. However, updated global data on metabolic dysfunction-associated steatohepatitis...
8.
Zhou X, Yip T, Huang D, Muthiah M, Noureddin M, Zheng M
Clin Mol Hepatol
. 2024 Dec;
PMID: 39722613
No abstract available.
9.
Danpanichkul P, Duangsonk K, Tham E, Tothanarungroj P, Auttapracha T, Prasitsumrit V, et al.
Alcohol Clin Exp Res (Hoboken)
. 2024 Dec;
49(2):368-378.
PMID: 39701596
Background: To investigate the trends in alcohol-associated liver disease (ALD), liver cancer from alcohol, and alcohol use disorder (AUD) burden among older adults in the United States (US). Methods: We...
10.
Danpanichkul P, Suparan K, Kaeosri C, Jatupornpakdee P, Attia A, Suenghataiphorn T, et al.
Clin Gastroenterol Hepatol
. 2024 Dec;
PMID: 39694213
Background & Aims: Metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH) are the leading causes of liver disease and are emerging as the main risk factors for...